ADMA Biologics (NASDAQ:ADMA) Stock Rating Reaffirmed by HC Wainwright

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Monday, Marketbeat Ratings reports. They currently have a $18.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 8.56% from the stock’s previous close.

Several other brokerages have also issued reports on ADMA. Mizuho raised their target price on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Stock Up 1.3 %

Shares of ADMA opened at $16.58 on Monday. ADMA Biologics has a 52 week low of $3.06 and a 52 week high of $21.13. The stock has a market capitalization of $3.84 billion, a price-to-earnings ratio of -829.00 and a beta of 0.62. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The stock has a fifty day moving average of $17.91 and a 200-day moving average of $12.53.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.02) EPS. As a group, sell-side analysts anticipate that ADMA Biologics will post 0.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently added to or reduced their stakes in the stock. Creative Planning boosted its stake in ADMA Biologics by 52.0% during the 3rd quarter. Creative Planning now owns 54,947 shares of the biotechnology company’s stock valued at $1,098,000 after purchasing an additional 18,800 shares during the last quarter. Inspire Investing LLC boosted its stake in ADMA Biologics by 101.9% during the 3rd quarter. Inspire Investing LLC now owns 64,667 shares of the biotechnology company’s stock valued at $1,293,000 after purchasing an additional 32,645 shares during the last quarter. Contravisory Investment Management Inc. acquired a new position in ADMA Biologics during the 3rd quarter valued at about $216,000. USA Financial Formulas boosted its stake in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 539 shares during the last quarter. Finally, CWM LLC boosted its stake in ADMA Biologics by 72.5% during the 3rd quarter. CWM LLC now owns 14,129 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 5,937 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.